Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Replimune (REPL) Research & Development (2017 - 2025)

Replimune has reported Research & Development over the past 9 years, most recently at $53.1 million for Q4 2025.

  • Quarterly results put Research & Development at $53.1 million for Q4 2025, up 10.7% from a year ago — trailing twelve months through Dec 2025 was $222.8 million (up 25.89% YoY), and the annual figure for FY2025 was $189.4 million, up 8.28%.
  • Research & Development reached $53.1 million in Q4 2025 per REPL's latest filing, down from $57.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $57.9 million in Q3 2025 and bottomed at $16.2 million in Q1 2021.
  • Median Research & Development over the past 5 years was $41.5 million (2023), compared with a mean of $37.7 million.
  • The largest annual shift saw Research & Development skyrocketed 74.61% in 2023 before it dropped 11.51% in 2024.
  • Over 5 years, Research & Development stood at $19.4 million in 2021, then soared by 56.36% to $30.3 million in 2022, then soared by 41.59% to $42.8 million in 2023, then increased by 12.04% to $48.0 million in 2024, then grew by 10.7% to $53.1 million in 2025.
  • Business Quant data shows Research & Development for REPL at $53.1 million in Q4 2025, $57.9 million in Q3 2025, and $57.8 million in Q2 2025.